The Oncology Institute, Inc. (STLN) AI Stock Analysis

Starling Oncology, Inc., founded in 2007 and headquartered in Cerritos, California, provides oncology services across the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services. It also manages palliative care programs, combined community clinics, and infusion suites, while offering educational seminars, counseling, and 24/7 patient support. Its specialty pharmacy includes in-office and mail-order dispensing for oral and self-injectable cancer medications, serving adult and senior cancer patients.

Top-line revenue expanded at a 3-year CAGR of 25.8% from $252.5M in FY2022 to $502.7M in FY2025, driven by annual growth rates of 28.4% in FY2023, 21.3% in FY2024, and 27.8% in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $587.2M, with quarterly revenue growing 34.6% year-over-year. Operating margin improved from -28.5% in FY2022 to -7.2% in FY2025 and reached -2.9% for the trailing twelve months. Net losses were -$83.1M in FY2023, -$64.7M in FY2024, and -$60.6M in FY2025, yielding an improved net margin of -12.1% in FY2025 compared to -25.6% in FY2023. TTM EPS was -$0.29.

As of June 30, 2026, the company held $41.1M in cash and short-term investments against $104.5M in total debt, resulting in net debt of $63.4M. Shareholders' equity remained negative at -$24.9M on total assets of $178.2M. The company's current ratio stood at 1.36. Cash flow from operations improved from -$61.8M in FY2022 to -$24.6M in FY2025, while free cash flow was -$27.8M in FY2025 after $3.2M in capital expenditures.

STLN carries an enterprise value of $759.0M and trades at a price-to-sales ratio of 1.1x and an EV-to-EBITDA multiple of 8.5x. Both multiples represent discounts compared to the median of its US-listed Healthcare peers, which trade at a price-to-sales ratio of 4.1x and an EV-to-EBITDA ratio of 12.0x. Over the past year, the stock gained 69.7%, outperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year period, the stock returned -35.4% versus an 83.0% gain for the index.

Wall Street analysts hold a positive outlook on STLN, with 4 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings. The mean price target of $9.40 represents an upside of 46.2% above the October 16, 2026 closing price of $6.43. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $665.0M and EPS of -$0.16. For FY2027, 4 analysts project revenue of $884.0M and breakeven EPS of $0.00. The company beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 12, 2026.

This page is an AI-written research summary of The Oncology Institute, Inc. (STLN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STLN income statement, STLN balance sheet, STLN key metrics, STLN analyst forecast, STLN chart. See the STLN stock overview for the latest quote and news.